

Irun Bhan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3431091/publications.pdf>

Version: 2024-02-01

13
papers

435
citations

1307594

7
h-index

1199594

12
g-index

14
all docs

14
docs citations

14
times ranked

928
citing authors

#	ARTICLE	IF	CITATIONS
1	An RNA-based signature enables high specificity detection of circulating tumor cells in hepatocellular carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 1123-1128.	7.1	133
2	Barriers to Use of Palliative Care and Advance Care Planning Discussions for Patients With End-Stage Liver Disease. Clinical Gastroenterology and Hepatology, 2019, 17, 2592-2599.	4.4	67
3	Pre-emptive pangenotypic direct acting antiviral therapy in donor HCV-positive to recipient HCV-negative heart transplantation: an open-label study. The Lancet Gastroenterology and Hepatology, 2019, 4, 771-780.	8.1	66
4	Pancreatic circulating tumor cell profiling identifies LIN28B as a metastasis driver and drug target. Nature Communications, 2020, 11, 3303.	12.8	55
5	Physicians' Perspectives on Palliative Care for Patients With End-Stage Liver Disease: A National Survey Study. Liver Transplantation, 2019, 25, 859-869.	2.4	40
6	Immediate administration of antiviral therapy after transplantation of hepatitis C-infected livers into uninfected recipients: Implications for therapeutic planning. American Journal of Transplantation, 2020, 20, 1619-1628.	4.7	31
7	Detection and Analysis of Circulating Epithelial Cells in Liquid Biopsies From Patients With Liver Disease. Gastroenterology, 2018, 155, 2016-2018.e11.	1.3	29
8	Partial splenic embolization is superior to intravenous somatostatin for decreasing portal pressure in cirrhotic patients: a dynamic self-controlled cohort study. Scandinavian Journal of Gastroenterology, 2020, 55, 1341-1346.	1.5	3
9	Hepatology Consultants Often Disagree on Etiology of Abnormal Liver Biochemistries in COVID-19 but Agree on Management. Digestive Diseases and Sciences, 2021, 66, 1852-1854.	2.3	3
10	Spontaneous Immune-Mediated Regression of Hepatocellular Carcinoma With High Tumor Mutational Burden. JCO Precision Oncology, 2021, 5, 1040-1043.	3.0	2
11	PLSec: A novel, liquid biomarker for HCC risk. Med, 2021, 2, 788-790.	4.4	1
12	Reply. Gastroenterology, 2019, 156, 1933-1934.	1.3	0
13	Hepatic vascular remodelling in a patient with dyskeratosis congenita. Histopathology, 2021, , .	2.9	0